Inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers
- 1 January 2016
- journal article
- Published by Elsevier in Acta Biomaterialia
- Vol. 29, 352-364
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
This publication has 91 references indexed in Scilit:
- Dendrimers for siRNA DeliveryPharmaceuticals, 2013
- Mesoporous bioactive glasses: structure characteristics, drug/growth factor delivery and bone regeneration applicationInterface Focus, 2012
- Bioactive glass in tissue engineeringActa Biomaterialia, 2011
- Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lungEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Small Interfering RNA Knocks Down the Molecular Target of Alendronate, Farnesyl Pyrophosphate Synthase, in Osteoclast and Osteoblast CulturesMolecular Pharmaceutics, 2010
- siRNA Knock-Down of RANK Signaling to Control Osteoclast-Mediated Bone ResorptionPharmaceutical Research, 2010
- Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 TherapyMolecular Therapy, 2008
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- Strategies for silencing human disease using RNA interferenceNature Reviews Genetics, 2007
- Osteoclast differentiation and activationNature, 2003